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ARTICLE OPEN
Cyclin E expression is associated with high levels of replication
stress in triple-negative breast cancer
Sergi Guerrero Llobet1, Bert van der Vegt 2, Evelien Jongeneel2, Rico D. Bense1, Mieke C. Zwager2, Carolien P. Schröder1,
Marieke Everts1, Rudolf S. N. Fehrmann 1, Geertruida H. de Bock3 and Marcel A. T. M. van Vugt 1✉
Replication stress entails the improper progression of DNA replication. In cancer cells, including breast cancer cells, an important
cause of replication stress is oncogene activation. Importantly, tumors with high levels of replication stress may have different clinical
behavior, and high levels of replication stress appear to be a vulnerability of cancer cells, which may be therapeutically targeted by
novel molecularly targeted agents. Unfortunately, data on replication stress is largely based on experimental models. Further
investigation of replication stress in clinical samples is required to optimally implement novel therapeutics. To uncover the relation
between oncogene expression, replication stress, and clinical features of breast cancer subgroups, we immunohistochemically
analyzed the expression of a panel of oncogenes (Cyclin E, c-Myc, and Cdc25A,) and markers of replication stress (phospho-Ser33-
RPA32 and γ-H2AX) in breast tumor tissues prior to treatment (n= 384). Triple-negative breast cancers (TNBCs) exhibited the highest
levels of phospho-Ser33-RPA32 (P < 0.001 for all tests) and γ-H2AX (P < 0.05 for all tests). Moreover, expression levels of Cyclin E (P <
0.001 for all tests) and c-Myc (P < 0.001 for all tests) were highest in TNBCs. Expression of Cyclin E positively correlated with phospho-
RPA32 (Spearman correlation r= 0.37, P < 0.001) and γ-H2AX (Spearman correlation r= 0.63, P < 0.001). Combined, these data
indicate that, among breast cancers, replication stress is predominantly observed in TNBCs, and is associated with expression levels
of Cyclin E. These results indicate that Cyclin E overexpression may be used as a biomarker for patient selection in the clinical
evaluation of drugs that target the DNA replication stress response.
npj Breast Cancer            (2020) 6:40 ; https://doi.org/10.1038/s41523-020-00181-w
INTRODUCTION
Breast cancers are the most frequently diagnosed neoplasms
worldwide, with approximately 1.38 million women being
diagnosed with breast cancer worldwide every year. One-third
of these women subsequently die of this disease, accounting for
~14% of all cancer-related deaths in women1. Therefore, there is
an urgent clinical need for improved breast cancer treatment.
Breast cancers are very heterogeneous, and multiple classification
methods have been developed to stratify patient groups. Using
gene expression profiling, at least six major breast cancer subgroups
have been defined, including “normal-like”, “luminal A”, “luminal B”,
“HER2-enriched”, “claudin-low”, and “basal-like”2. Furthermore,
combining copy number variations with gene expression analysis
allowed identification of ten clusters that are associated with
differential clinical outcome3. In standard care, breast cancers are
subtyped based on the expression of the estrogen and progester-
one receptors (ER and PR) and the human epidermal growth factor
receptor-2 (HER2), as these receptors are “oncogenic drivers” and
relevant drug targets. Patients with breast cancers that do not
express the ER, PR, and HER2, so-called triple-negative breast cancers
(TNBCs), do not benefit from antihormonal or anti-HER2-targeted
treatments, and rely on conventional chemotherapeutic regimens.
Initially, high response rates to conventional chemotherapeutics are
seen in TNBC, however, tumors often recur and women have a poor
prognosis overall4. TNBCs display aggressive behavior, and account
for ~15–20% of all invasive breast cancers4.
TNBC tumors show a large degree of overlap with the intrinsic
“basal‐like” and “claudin‐low” subgroups, lack common “drug-
gable” aberrations, but share a profound genomic instability5.
Finding novel treatment options for such genomically instable
cancers is not only relevant for TNBCs, but also for other hard-to-
treat cancers with extensive genomic instability, including ovarian
and pancreatic cancers6,7.
Evidence is increasingly pointing to “replication stress” as a driver
of genomic instability8,9. DNA replication is initiated at certain
genomic loci called “replication origins”9. Replication origins are fired
in a temporally controlled way, which prevents exhaustion of the
nucleotide pool. A key source of replication stress in cancer cells
appears to be the uncoordinated firing of replication origins due to
oncogene activation8–11. As a consequence, oncogene activation
depletes the nucleotide pool, leading to slowing or complete stalling
of replication forks12. Oncogenes that have been linked to the
induction of replication stress are the transcription factor c-Myc13
and Cyclin E, which acts in conjunction with cyclin-dependent
kinase-2 (CDK2) to promote S-phase entry. It was shown that Cyclin
E overexpression triggers aberrant origin firing with consequent
nucleotide pool depletion, leading to replication fork stalling and
genomic instability12,14. Likewise, overexpression of the Cdc25A
phosphatase, which activates CDK2, promotes premature cell cycle
progression and genomic instability15–17.
Cells are equipped with multiple mechanisms to survive
replication stress. During replication fork stalling, single-stranded
DNA (ssDNA) is exposed and rapidly activates the so-called
“replication checkpoint”, in which the ATR kinase is the central
player18. Activation of the replication checkpoint facilitates the
rapid coating of ssDNA at replication forks with replication
protein-A (RPA), which is phosphorylated by ATR19,20. When
stalled replication forks are not resolved in time, they can collapse
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and cause DNA double-strand breaks (DSBs), triggering phosphor-
ylation of the histone variant H2AX at serine 139, which is referred
to as γ-H2AX21.
Genomically instable tumors increasingly rely for their survival
on mechanisms that allow cells to resolve replication stress-
induced DNA lesions, including cell cycle checkpoints22. Hence,
cell cycle checkpoint kinases, including WEE1 and ATR, are
potential therapeutic targets for tumors with high levels of
replication stress. In order to implement novel therapeutic agents
that target tumors with high levels of replication stress optimally,
it is essential to know which tumor subgroups display replication
stress. To this end, and to find potential biomarkers for tumors
with high levels of replication stress, we examined replication
stress levels in relation to oncogene expression and clinicopatho-
logical data in a consecutive well-defined series of breast cancer
samples.
RESULTS
Overexpression of Cyclin E1 results in replication stress and
increased sensitivity to ATR and WEE1 inhibition
To study the potential effects of Cyclin E1, encoded by the CCNE1
gene, on DNA replication kinetics in vitro, we transduced MDA-
MB-231 TNBC cells with a doxycycline-inducible Cyclin E1
construct (Fig. 1a). Cells were treated for 48 h with doxycycline
to induce Cyclin E1 overexpression, and were then sequentially
labeled with the thymidine analogues CldU and IdU to probe
replication kinetics (Fig. 1b). Measurement of individual IdU tract
lengths revealed that overexpression of Cyclin E1 resulted in a
reduction in ongoing DNA synthesis speed of approximately 25%
(Fig. 1c). To assess whether Cyclin E1 overexpression affects the
sensitivity of cancer cells to inhibitors of cell cycle checkpoint
kinases, we induced Cyclin E1 overexpression and inhibited ATR
and WEE1 kinases using VE-822 and MK-1775 respectively (Fig. 1d,
Supplementary Table 1). Induction of Cyclin E1 overexpression
increased the sensitivity to ATR and WEE1 inhibitors in MDA-
MB231 cells, as assessed using MTT assays (Fig. 1d). Taken
together, overexpression of Cyclin E1 results in replication stress in
TNBC cells and enhanced the sensitivity towards inhibitors of the
WEE1 and ATR cell cycle checkpoint kinases.
Analysis of breast cancer tissues
To further investigate oncogene-induced replication stress in
clinical samples, we selected a study population that comprised
384 breast cancer patients (Fig. 2a), whose baseline clinical,
pathological and treatment characteristics are summarized in
Supplementary Table 2. Breast cancer patients were divided into
four subgroups according to their hormone receptor status and
HER2 expression. Molecular subgroup analysis showed that our
cohort consisted of n= 161 ER/PR+HER2−, n= 90 ER/PR+HER2+,
n= 27 ER/PR−HER2+, and n= 106 ER/PR−HER2− (TNBC) patients
(Supplementary Table 2). Compared to other patient subgroups,
the median age at diagnosis was lowest for TNBC patients,
followed by ER/R−HER2+ patients23 (Supplementary Table 2). In
addition, tumor grade significantly varied across breast cancer
subgroups (Supplementary Table 2, P= 1.72 × 10−13), and was
highest in patients with TNBC (Supplementary Table 2, P < 0.05 for
all tests). In accordance with treatment guidelines, chemotherapy
was most frequently used in TNBC patients (66.0%), whereas
radiotherapy and endocrine therapy were more frequently used in
non-TNBC patients (Supplementary Table 3, P < 0.001 for all tests).
Expression of Cyclin E, c-Myc, and Cdc25A in breast cancer
subgroups
We next performed immunohistochemical analysis in breast
cancer tissues taken prior to treatment (Supplementary Table 4)
to examine the expression levels of Cyclin E (encoded by CCNE1)
and c-Myc (encoded by MYC), two oncogenes that are frequently
amplified in TNBC, and have been associated with replication
stress in experimental models24–27 (Fig. 2b). For Cyclin E, we
separately assessed nuclear and cytoplasmic Cyclin E (Fig. 2b),
since cytoplasmic Cyclin E has been related to reduced breast
cancer survival28,29. We also assessed expression of the Cdc25A
phosphatase (Fig. 2b). Although Cdc25A is less frequently over-
expressed in breast cancer15, Cdc25A overexpression is frequently
used to induce replication stress in experimental models30, and
has been linked to oncogenic activity31,32, and for that reason was
included in our analysis.
Expression levels of nuclear Cyclin E were significantly higher in
TNBC than in the other breast cancer subgroups (Supplementary
Table 5, and Fig. 2c, P < 0.05 for all tests). In contrast, cytoplasmic
Cyclin E levels were high in both TNBC and ER/PR−HER2+ tumors,
compared to ER/PR+HER2− tumors (Supplementary Table 5 and
Fig. 2c, P < 0.05 for all tests). Expression levels of c-Myc were also
higher in TNBC (Supplementary Table 5 and Fig. 2c, P < 0.001)
compared to the other subgroups. Although TNBC tumors also
displayed the highest levels of Cdc25A, these differences were not
statistically significant (Supplementary Table 5 and Fig. 2c). We
next analyzed mRNA expression levels of CCNE1, MYC, and
CDC25A in a set of 7270 gene expression profiles from primary
breast tumors obtained from the Gene Expression Omnibus
(GEO)33. The mRNA expression of CCNE1, MYC, and to a lesser
extend CDC25A were significantly higher in TNBC when compared
to the other subgroups (Fig. 2d). These findings confirm at the
mRNA level that, among breast cancer subgroups, TNBCs
exhibited the highest expression levels of Cyclin E, c-Myc and
Cdc25A.
Levels of replication stress in breast cancer subgroups
To determine levels of replication stress, we immunohistochemi-
cally examined the expression of phosphorylated RPA33 (further
referred to as pRPA) in breast cancer tissues taken prior to
treatment. In addition, we analyzed the expression of γ-H2AX, an
established marker for collapsed replication forks and double-
strand breaks, which are consequences of replication stress34,35.
Representative immunohistochemical pRPA and γ-H2AX stainings
are shown in Fig. 3a. We also compared expression of pRPA and γ-
H2AX with other DNA damage response components in a subset
of samples. Specifically, we immunohistochemically stained n= 45
cases for 53BP1 and FANCD2, two proteins involved in the repair
of DNA lesions induced by replication stress (Supplementary Fig.
1a). High levels of 53BP1 were present in all cases analyzed
(Supplementary Fig. 1b), whereas expression levels of
FANCD2 showed larger variation (Supplementary Fig. 1b).
Importantly, we found that expression of γ-H2AX and FANCD2
were associated (Supplementary Fig. 1c, r= 0.344, P= 0.028), in
line with their roles in resolving the consequences of replication
stress-induced DNA lesions. In contrast, 53BP1 expression did not
show statistically significant associations with expression of either
pRPA or γ-H2AX (Supplementary Fig. 1c).
Analysis of pRPA staining revealed that TNBC tumors displayed
highest expression levels (Supplementary Table 5, Fig. 3b).
Moreover, TNBC tumors showed higher pRPA levels than the
combined non-TNBC tumors (Fig. 3c, P= 3.79 × 10−9). Also, γ-
H2AX scores from TNBC tumors were significantly higher than ER/
PR+/HER2− and ER/PR+/HER2+ status (Supplementary Table 5, Fig.
3b, P= 1.50 × 10−5 and P= 0.035, respectively). Again, TNBC
tumors displayed higher levels of γ-H2AX expression when
compared to the combined group of non-TNBCs (Fig. 3c, P=
3.42 × 10−4). These data indicate that the expression of replication
stress markers varies among breast cancer subgroups, with TNBCs
and ER/PR−HER2+ tumors exhibiting highest levels.
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Since the highest expression levels of c-Myc and Cyclin E as
well as replication stress markers were observed in TNBC, we
further analyzed relevant TNBC subgroups. Expression of the
androgen receptor (AR) has been described to define a TNBC
subgroup with distinct characteristics36. In our cohort, n= 29
out of 106 TNBC cases (27.4%) expressed the AR (Supplemen-
tary Fig. 2a, Supplementary Table 6a, b). We next analyzed the
expression levels of replication stress markers in TNBC-AR− and
TNBC-AR+ subgroups (Supplementary Fig. 2b). Tumor expres-
sion of pRPA (Supplementary Fig. 2b, Supplementary Table 6a,
P= 0.686) and γ-H2AX (Supplementary Fig. 2b, Supplementary
Table 6a, P= 0.798) were not statistically different between the
AR+ vs. AR− TNBC cases. Likewise, tumor expression of
oncogenes was similarly distributed in TNBC-AR− and TNBC-
AR+ subgroups (Supplementary Fig. 2b and Supplementary
Table 6b, P > 0.05 for all tests). These data indicate that in this
cohort, expression of replication stress markers and expression
of oncogenes are similarly distributed in TNBC-AR− and TNBC-
AR+ subgroups.
Correlations between replication stress markers and Cyclin
E, c-Myc, and Cdc25A expression
To determine whether expression of Cyclin E, c-Myc, or Cdc25A
was associated with replication stress in our study population, we
examined associations between expression of Cdc25A, Cyclin E,
and c-Myc with expression of replication stress markers pRPA and
γ-H2AX. We first analyzed associations of replication stress markers
with oncogene expression as continuous variables (Table 1),
because no clear biphasic distributions of staining intensities were
observed. Expression levels of pRPA were positively correlated
with those of c-Myc (Table 1, r= 0.26, P < 0.001), as well as
expression levels of nuclear Cyclin E (Table 1, r= 0.37, P < 0.001)
and cytoplasmic Cyclin E (Table 1, r= 0.28, P < 0.001) in the entire
cohort. Among breast cancer subgroups, the strongest correla-
tions were found in TNBC between Cyclin E and pRPA expression
(Table 1, r= 0.43, P < 0.001), and between c-Myc and pRPA (Table 1,
r= 0.36, P < 0.001). Furthermore, Cyclin E expression was strongly
correlated with levels of γ-H2AX staining (Table 1, r= 0.63, P <
0.001). Spearman correlation analysis of breast cancer subgroups
revealed that the association between nuclear Cyclin E and
γ-H2AX expression was strongest in ER/PR−HER2+ (Table 1,
r= 0.86, P < 0.001) and TNBC (Table 1, r= 0.71, P < 0.001).
Combined, these data indicate that expression of Cyclin E is
associated with expression of replication stress markers in our
study population, especially in the TNBC and ER/PR−HER2+
subgroups.
Similar associations were observed when we dichotomized
samples on the basis of oncogene expression. Specifically, Cyclin E
stainings were categorized into nuclear and cytoplasmic negative
(N−/C−, n= 113), nuclear positive and cytoplasmic negative
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Cyclin E1 +dox: IC50: 0.227
empty +dox: IC50: 0.329 p=0.002
Cyclin E1 +dox: IC50: 0.173
empty +dox: IC50: 0.309 p<0.001
Fig. 1 Overexpression of Cyclin E1 results in replication stress and increased sensitivity to ATR and WEE1 inhibition. a Immunoblotting of
Cyclin E1 and β-Actin at 48 h after doxycycline addition to MDA-MB-231 cells. b Cells were treated with doxycycline as described for panel a.
Subsequently, cells were pulse-labeled for 20min with CldU (25 µM) and subsequently pulse-labeled for 20min with IdU (250 µM).
Representative DNA fibers are shown. Scale bar indicates 10 µm. c Quantification of IdU DNA fiber lengths as described in panel b. Per
condition, 300 fibers were analyzed and individual datapoints and corresponding medians are shown. d MDA-MB-231 cell induced to express
Cyclin E1 were treated for 4 days with ATR inhibitor (VE-822) in a range from 0 to 3.2 µM, or WEE1 inhibitor (MK-1775) in a range from 0 to
1.28 µM. Subsequently, MTT conversion was analyzed. Per experiment, six technical replicates per condition were included. Averages and
standard deviations are plotted. Indicated P values were calculated to compare the relative MTT conversion between MDA-MB231 cells
(Empty+dox vs. Cyclin E1+dox) using two-tailed Student’s t test. *Indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, **** indicates P
< 0.0001. Mean IC50 values are indicated, and were statistically tested using a two-tailed Student’s t test. Additional comparisons between
MDA-MB231 cells are provided in Supplementary Table 1.
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positive or nuclear negative (C+, n= 193) (Table 2 and Fig. 3d). In
line with our earlier results (Fig. 3b), we observed that highest
pRPA and γ-H2AX expression levels were found in the TNBC
subgroups with Cyclin E C+ (n= 63) and N+/C− (n= 29) as well
as ER/PR−HER2+ subgroup with Cyclin E C+ (n= 16) and N+/C−
(n= 7). In parallel, we dichotomized samples based on Cdc25A or
c-MYC expression (Supplementary Fig. 3). High expression levels
of Cdc25A did not show strong associations with increased levels
of pRPA or γ-H2AX in breast cancer subgroups (Supplementary
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increased levels of pRPA, predominantly in the TNBC subgroup
(Supplementary Fig. 3).
AR status vs. expression of oncogenes and markers of replication
stress
To test whether the association between oncogene expression
and expression of replication stress markers was affected by AR
expression in TNBCs, Spearman correlation analyses were
performed. A stronger association between pRPA and Cyclin E
was observed in AR-negative TNBCs (Supplementary Table 7a, r=
0.463, P < 0.001), when compared to AR-positive TNBCs (Supple-
mentary Table 7a, r= 0.327, P= 0.083). Similarly, Spearman
correlation analysis underscored that the association between
Cyclin E and γ-H2AX was stronger in AR-negative tumors
(Supplementary Table 7b, r= 0.755, P < 0.05) than in AR-positive
tumors (Supplementary Table 7b, r= 0.574, P= 0.001). In line with
this observation, Cdc25A and Cyclin E showed weaker associations
in AR-positive tumors (Supplementary Table 7a, Cdc25A: r=
−0.214, P= 0.265; Cyclin E: r= 0.092, P= 0.637), than in AR-
negative tumors (Supplementary Table 7a, Cdc25A: r= 0.131, P=
0.256; Cyclin E: r= 0.320, P= 0.005). In addition, AR-negative
tumors showed stronger associations between γ-H2AX and
Cdc25A (Supplementary Table 7b, r= 0.275, P= 0.016) and
between γ-H2AX and Cyclin E (Supplementary Table 7b, r=
0.118, P= 0.306) than AR-positive tumors (Supplementary Table
7b, Cdc25A: r=−0.100, P= 0.607 and (Cyclin E: r= 0.048, P=
0.806). In conclusion, markers of replication stress appear equally
expressed in AR-negative and AR-positive TNBCs, although the
associations between replication stress (pRPA, γ-H2AX) and
oncogene expression (Cdc25A, Cyclin E) are strongest in AR-
negative TNBCs within our cohort.
Associations of expression of replication stress markers with
clinicopathological characteristics and tumor expression of Cyclin
E, c-Myc and Cdc25A
Linear regression analyses were performed to evaluate the relation
between expression of replication stress markers versus clinico-
pathological characteristics and tumor expression of Cdc25A,
Cyclin E, and c-Myc. Univariate regression analysis showed that
pRPA was associated with γ-H2AX (Table 3, β= 0.409, P < 0.001).
Also, pRPA was associated with positivity for cytoplasmic Cyclin E
(Table 3, β= 0.345, P < 0.001). In contrast, weaker associations
were found between oncogene expression and pRPA levels (Table
3). The covariates from univariate regression analyses that
displayed P < 0.05 were included for multivariate analysis, and
showed that pRPA was weakly related to γ-H2AX (Table 3, β=
0.351, P < 0.001). Conversely, tumor expression of γ-H2AX was
associated with nuclear Cyclin E (Table 3, β= 0.407, P < 0.001) and
with cytoplasmic Cyclin E (Table 3, β= 0.324, P < 0.001). No strong
independent associations were found between clinicopathological
parameters and pRPA or γ-H2AX expression. In summary, our
findings indicate that replication stress measured with pRPA,
corrected for age, tumor subgroup, tumor grade, and tumor
expression, is related to γ-H2AX, whereas replication stress
quantified with γ-H2AX, corrected for tumor subgroup and tumor
expression, is positively associated with tumor expression of
nuclear and cytoplasmic Cyclin E.
Associations between expression of oncogenes and markers of
replication stress with survival
We next analyzed the relationship between the expression of
Cyclin E, c-MYC, Cdc25A, and markers of replication stress with
disease-free survival (DFS), recurrence-free survival (RFS) or overall
survival (OS) in our breast cancer cohort (n= 379) using Cox
regression analyses (Table 4). Univariate analyses showed that
positivity of nuclear Cyclin E expression was associated with worse
OS (Table 4, β= 0.633, P= 0.035) and borderline associated with
DFS (Table 4, β= 0.565, P= 0.058) but not RFS (Table 4, β= 0.162,
P= 0.619). Concerning MYC expression, high expression was also
associated with poor OS (Table 4, β= 0.535, P= 0.023) and DFS
(Table 4, β= 0.555, P= 0.019). For multivariate Cox regression
analyses, age, tumor size, tumor grade, lymph node involvement,
ER status, HER2 status, and treatment regimen were included
(Table 4) and were not associated with expression of Cyclin E,
Cdc25A, c-Myc or γ-H2AX.
Next, we analyzed DFS on the basis of those publicly available
patient data retrieved from GEO, of which also clinical data was
available (n= 3450 out of n= 7270). A shorter DFS was found in
patients with ER+/HER2+ (n= 341) and ER−/HER2+ (n= 291)
tumors, when compared to other subgroups (Supplementary Fig.
4a), and a shorter OS in the TNBC (n= 263) and ER−/HER2+ (n=
341) patients (Supplementary Fig. 4b). When we evaluated the
relation between CCNE1 mRNA expression and DFS (n= 846) or
OS (n= 632) using multivariate Cox regression analysis of data
from publicly available mRNA samples of primary breast tumors,
we found no associations between CCNE1 mRNA expression and
DFS. In contrast, a higher mRNA expression level of CCNE1 was
associated with reduced OS (Supplementary Table 8, HR= 1.660,
P= 0.004) in the ER+/HER2− subgroup (n= 417).
DISCUSSION
In the present study, we examined the relation between oncogene
expression and replication stress marker expression in breast
cancer subgroups. Our immunohistochemical analyses show that
levels of replication stress and oncogene expression vary among
breast cancer subgroups and that the highest expression levels of
replication stress markers and oncogenes were found in the TNBC
and ER/PR−HER2+ subgroups. Furthermore, both nuclear and
cytoplasmic Cyclin E expression, and to a lesser extend c-Myc
expression, were strongly associated with the levels of replication
stress. These findings are relevant in the context of ongoing
clinical studies using novel agents that target replication stress, for
which proper patient selection is warranted.
Previous immunohistochemical studies showed that Cdc25A
was highly expressed in 69.6% of human breast carcinomas
analyzed (n= 46)37. A second study revealed that Cdc25A was
overexpressed in 47% of breast cancer cases, in a cohort of 144
patients15. In comparison, in the present study 29.5% of tumors
displayed strong Cdc25A staining intensity. Cdc25A has also been
shown to be overexpressed in other cancer types, including
Fig. 2 Analysis of immunohistochemical stainings and mRNA profiles in breast cancer patients. a Flow diagram indicating selection of
patients included for immunohistochemical and clinicopathological analyses. b Analysis of staining intensities of oncogenes (n= 384),
including cytoplasmic (c) and nuclear (n) Cyclin E, c-Myc, and Cdc25A. c Patients from the combined cohort (n= 384) and breast cancer
subgroups ER/PR+HER2− (n= 161), ER/PR+HER2+ (n= 90), ER/PR−HER2+ (n= 27) and TNBC (n= 106) were analyzed. Tumor tissue was
immunohistochemically scored for expression of oncogenes (Cyclin E (n), Cyclin E (c), c-Myc, Cdc25A). Indicated P values were calculated using
Mann–Whitney U test. d mRNA profiles of CCNE1, CDC25A, and MYC from breast cancer samples retrieved from the Gene Expression Omnibus
(GEO, n= 7270). Breast cancer subgroups ER/PR+HER2− (n= 4094), ER/PR+HER2+ (n= 812), ER/PR−HER2+ (n= 768) and TNBC (n= 1596) were
analyzed. Indicated P values were calculated using Mann–Whitney U test. Box plots indicate medians and interquartile range, whiskers
represent 10th and 90th percentile.
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Fig. 3 Expression of oncogenes and replication stress markers in breast cancer. a Analysis of staining intensities of replication stress
markers, γ-H2AX and pRPA32 (Ser33) in breast cancer TMAs (n= 384). (b) Patients from the combined cohort (n= 384) and breast cancer
subgroups ER/PR+HER2− (n= 161), ER/PR+HER2+ (n= 90), ER/PR−HER2+ (n= 27) and ER/PR−HER2− (n= 106) were analyzed. Tumor tissue was
immunohistochemically scored for expression of oncogenes (Cyclin E (n), Cyclin E (c), c-Myc, Cdc25A), indicated P values were calculated using
Mann–Whitney U test. Box plots represent medians and interquartile range. Whiskers represent 10th and 90th percentile. c TNBC patients (ER/
PR−HER2−, n= 106) were compared with non-TNBC breast cancers (n= 278) for expression of replication stress markers pRPA and γ-H2AX.
Box plots represent medians and interquartile range. Whiskers represent 10th and 90th percentile. d Tumor tissue from the combined cohort
(n= 384) was immunohistochemically scored for expression of oncogenes (Cyclin E (n), Cyclin E (c), Cdc25A and c-Myc). Cyclin E scores were
classified into nuclear and cytoplasm negative (N−/C−, n= 113), nuclear positive and cytoplasm negative (N+/C−, n= 78) and either nuclear
positive or negative and cytoplasm positive (C+, n= 193). An additional subclassification was performed based on breast cancer subgroups
ER/PR+HER2−, ER/PR+HER2+, ER/PR−HER2+ and TNBC. For all subgroups or the total cohort, tumor expression of replication stress markers
(pRPA and γ-H2AX) was assessed, indicated P values were calculated using Mann–Whitney U test. “Ns” indicates not significant. * indicates P <
0.05, ** indicates P < 0.01, *** indicates P < 0.001, **** indicates P < 0.0001. Medians and standard deviations are indicated.
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high-grade serous ovarian cancer and head-and-neck squamous
cell carcinoma31,38, which are characterized by genomic
instability39,40.
Concerning c-Myc expression, our results indicated that high c-
Myc expression was predominantly observed in TNBCs, and that c-
Myc expression was associated with expression of the replication
stress marker pRPA. These findings are in line with previous
reports, showing frequent MYC amplification in TNBC24. Impor-
tantly, our results provide confirmation that the link between c-
Myc-overexpression and induction of replication stress is also
observed in patient samples13,26,41.
CCNE1 is frequently amplified in TNBC, in line with our finding
that high levels of Cyclin E expression is most prominent in TNBC
cases24. Importantly, our observation that Cyclin E expression is
associated with expression of replication stress markers is in line
with experimental models, in which Cyclin E overexpression has
been shown to trigger a DNA damage response12,14,42. Specific
isoforms of Cyclin E, so-called low molecular-weight Cyclin E
isoforms (LMW-E) are suggested to accumulate in the cytoplasm
because they lack the NH2-terminal nuclear localization signal
43. In
line with experiments in which expression of cytoplasmic Cyclin E
was shown to induce various features that relate to replication
stress, including chromosome missegregation44, our data show
that expression of cytoplasmic Cyclin E, like expression of nuclear
Cyclin E, is associated with expression of replication stress markers
pRPA and γ-H2AX. Of note, we found that cytoplasmic and nuclear
Cyclin E showed a similar distribution among breast cancer
subgroups, with highest expression observed in TNBC. However,
no clear biphasic staining distributions of nuclear or cytoplasmic
Cyclin E were observed. For this reason, we analyzed the
expression of Cyclin E and other markers as continuous variables.
Survival analysis of our cohort of patients and publicly available
patient data showed that higher levels of replication stress (pRPA)
or high Cyclin E expression levels were associated with worse DFS,
whereas a higher nuclear Cyclin E levels was related with worse
OS, albeit only in univariate analysis. CCNE1 mRNA was not found
to be independently associated with DFS or OS in public data,
except in the ER+/HER2− subgroup, in which higher levels of
CCNE1 expression were associated with worse OS. Immunohisto-
chemical analysis of Cyclin E previously identified Cyclin E as an
independent predictor of survival45, although hormone receptor
status was not included in this analysis. Also, total and low-
molecular-weight Cyclin E levels, as assessed by Western blot,
were shown to be independent predictors of overall survival in a
breast cancer cohort46. Studies in other cancer types, including
serous ovarian cancers and endometrial carcinomas, also showed
that CCNE1 amplification or Cyclin E overexpression was
associated with more aggressive tumor features, but was not an
independent predictor factor of survival47–49. However, high Cyclin
E expression was shown to be a significant predictive marker for
survival in suboptimally debulked ovarian cancers50.
Table 1. Spearman rank correlation analysis of replication stress marker expression versus oncogene expression in the study population.
BC Subgroup
Combined cohort ER/PR+HER2− ER/PR+HER2+ ER/PR−HER2+ TNBC
n= 384 n= 161 n= 90 n= 27 n= 106
Variable pRPA
Cdc25A
Correlation −0.135 −0.269 −0.152 0.076 0.035
P value 0.008 0.001 0.153 0.707 0.719
Cyclin E (n)
Correlation 0.371 0.090 0.289 0.232 0.432
P value 5.61 × 10−14 0.258 0.006 0.245 4.00 × 10−6
Cyclin E (c)
Correlation 0.275 0.309 0.143 0.218 0.262
P value 4.25 × 10−8 6.50 × 10−5 0.180 0.274 0.007
c-Myc
Correlation 0.256 0.214 0.180 0.133 0.359
P value 3.59 × 10−7 0.006 0.090 0.509 1.58 × 10−4
Variable γ-H2AX
Cdc25A
Correlation −0.030 −0.140 −0.037 0.368 0.170
P value 0.561 0.076 0.732 0.059 0.081
Cyclin E (n)
Correlation 0.632 0.538 0.613 0.855 0.705
P value 3.07 × 10−44 1.80 × 10−13 1.34 × 10−10 1.40 × 10–8 3.53 × 10−17
Cyclin E (c)
Correlation 0.192 0.209 0.258 −0.260 0.078
P value 1.55 × 10−4 0.008 0.014 0.190 0.424
c-Myc
Correlation 0.129 0.113 0.032 0.214 −0.032
P value 0.011 0.153 0.763 0.283 0.743
Association analysis between oncogene expression and pRPA or γ-H2AX expression in the combined cohort (n= 384) and in breast cancer subgroups.
Oncogene expression was used as a continuous variable in a Spearman rank correlation analysis.
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Taken together, our findings indicate that among breast cancer
subgroups, TNBCs and ER/PR−HER2+ tumors are characterized by
overexpression of the c-Myc and Cyclin E oncogenes, and by
higher expression levels of replication stress markers. These
findings are relevant, as increasing numbers of drugs are being
developed that target cancer cells with high levels of replication
stress. Specifically, inhibitors of the cell cycle checkpoint kinases
Chk1 and ATR are currently being tested in combination with
genotoxic agents that interfere with DNA replication51,52. In
parallel, inhibitors of the WEE1 kinase have been developed. The
potential of WEE1 inhibition was early on attributed to high
levels of replication stress53 and preclinical data indicated that
WEE1 inhibition would be preferentially effective in Cyclin
E-overexpressing cancer cells54. In line with these data, ovarian
cancer patients that responded favorably to WEE1 inhibitor
treatment more frequently showed tumor overexpression of
Cyclin E55. Based on these observations, a clinical trial testing
WEE1 inhibitor treatment in patients selected on CCNE1
amplification is currently ongoing (clinicaltrials.gov identifier:
NCT03253679).
Although different cell cycle checkpoint inhibitors are already in
clinical development, an effective patient selection strategy is
required to identify those patients who might benefit from these
drugs. For breast cancer patients, our data underscore that
overexpression of nuclear and/or cytoplasmic Cyclin E could be
used as a selection criterion for treatment with drugs that target
replication stress, including inhibitors of WEE1 and ATR.
METHODS
Cell lines
TNBC cell lines MDA-MB-231 were obtained from ATCC (#HTB26) and were
maintained in Dulbecco’s Minimum Essential Media (DMEM, Thermofisher),
supplemented with 10% (v/v), fetal calf serum and 1% penicillin/
streptomycin (Gibco). MDA-MB-231 cells were grown at 37 °C in normoxic
conditions (20% oxygen and 5% CO2).
DNA cloning and retroviral transduction
MDA-MB-231 cells were engineered to express Cyclin E1 in a doxycycline-
inducible manner. First, cells were stably transduced with pRetroX-Tet-On
Advanced (Clontech). To this end, HEK-293T cells were transfected with
10 µg of pRetroX-Tet-On Advanced, 2.5 µg of pMDg and 7.5 µg of pMD-g/p
as described previously56. At 24, 36, and 48 h after transfection, virus-
containing supernatant was filtered and added to target cells, which were
subsequently selected for 7 days using geneticin (G418 Sulfate, 800 µg/mL,
Thermofisher). Next, MDA-MB-231 cells harboring pRetroX-Tet-On
Advanced were transduced with pRetroX-Tight-Pur containing CCNE1. To
this end, Human CCNE1 was PCR amplified from Rc-CycE, which was a gift
from Bob Weinberg (Plasmid #8963, Addgene)57 using the following oligos:
forward: 5′-CGCGGCCGCCATGAAGGAGGACGGCGGCGCG-3′, reverse: 5′-
GATGAATTCTCACGCCATTTCCGGCCC-3′. The resulting fragments were
cloned into pJET1.2/blunt, GeneJET, (ThermoFisher). CCNE1 was subcloned
into pRetroX-Tight-Pur using NotI and EcoRI restriction sites. Subsequently,
cell lines harboring pRetroX-Tet-On Advanced were transduced with
pRetroX-Tight-Pur containing CCNE1 or empty plasmid. After 3 rounds of
transduction, MDA-MB-231 cells were selected for 2 days with 1 µg/mL of
puromycin dihydrochloride (Sigma).
Western blotting
MDA-MB-231 cells were lysed in M-PER lysis buffer (Pierce), supplemented
with protease and phosphatase inhibitor cocktail (Thermo Scientific).
Protein content was measured using the Pierce BCA protein quantification
Kit (Thermo Scientific). Protein samples were separated using sodium
dodecyl sulfate-polyacrylamide gels (SDS-PAGE) and transferred to
polyvinylidene fluoride membranes (Immobilon). Membranes were
blocked in 5% skimmed milk (Sigma), in tris-buffered saline (TBS)
containing 0.05% Tween-20 (Sigma) and incubated overnight with primary
antibodies at 4 °C and subsequently incubated with secondary antibodies
for 1 h at room temperature. Primary antibodies used were mouse anti-
Cyclin E1 (Abcam, ab3927, 1:500) and mouse anti-β-actin (MpBiomedicals,
69100, 1:10,000). Secondary antibodies used were horseradish peroxidase-
linked anti-mouse IgG (1:2000, DAKO) and visualized using chemilumines-
cence (Lumi-Light, Roche Diagnostics) on a Bio-Rad bioluminescence
device. Protein imaging was performed using Image Lab software (Bio-
Rad). All blots derive from the same experiment and were processed in
parallel.
DNA fiber analysis
To assess replication dynamics, MDA-MB-231 doxycycline-inducible cell
lines were pulse-labeled with CldU (25 µM) for 20min. Next, cells were
washed with warm medium and pulse-labeled with IdU (250 µM) for
20min. Cells were collected using trypsin and lysed on top of a microscope
slide in lysis solution (0.5% SDS, 200mM Tris [pH 7.4], 50 mM EDTA). DNA
fibers were spread by tilting the microscope slide and were subsequently
Table 2. Regression analysis of replication stress marker expression
versus oncogene expression in the study population.
BC subgroup Mean SD P5 P50 P95
γ-H2AX score
Cyclin E (N+/C−)
Combined cohort (n= 113) 5.3 8.2 0 1.7 26.3
ER/PR+HER2− (n= 64) 3.6 5.9 0 1 19.2
ER/PR+HER2+ (n= 31) 7.8 10.6 0 2.5 35
ER/PR−HER2+ (n= 4) 12.1 15.3 3.3 5 –
TNBC (n= 14) 5.2 7 0 2.9 –
Cyclin E (N+/C−)
Combined cohort (n= 78) 39 42.3 0 20.8 112.7
ER/PR+HER2− (n= 31) 37.4 44.8 0 17.5 133.8
ER/PR+HER2+ (n= 11) 30.8 36.3 0 7.5 –
ER/PR−HER2+ (n= 7) 59 37.8 10.8 54.2 –
TNBC (n= 29) 39.1 43.1 0 20.8 147.3
Cyclin E (C+)
Combined cohort (n= 193) 27.2 34.8 0 9.2 102.9
ER/PR+HER2− (n= 66) 23.9 35.4 0 6.3 104
ER/PR+HER2+ (n= 48) 26.5 30 0 10 99.9
ER/PR−HER2+ (n= 16) 22.6 32.3 0 7.9 –
TNBC (n= 63) 32.4 38.1 0 15 119.5
pRPA score
Cyclin E (N−/C−)
Combined cohort (n= 113) 120.2 44.5 8 121.7 192.9
ER/PR+HER2− (n= 64) 119.4 45.8 6.3 122.9 195.9
ER/PR+HER2+ (n= 31) 121 39.6 2.2 118.3 182
ER/PR−HER2+ (n= 4) 138.8 43.6 98.3 130 –
TNBC (n= 14) 116.9 52.5 10 123.3 –
Cyclin E (N+/C−)
Combined cohort (n= 78) 137 49.3 42.8 118.3 200
ER/PR+HER2− (n= 31) 120 54.1 10 109.2 200
ER/PR+HER2+ (n= 11) 126.5 42.6 44.2 115 –
ER/PR−HER2+ (n= 7) 146.7 38.1 103.3 139.2 –
TNBC (n= 29) 156.9 42.3 81.3 173.3 200
Cyclin E (C+)
Combined cohort (n= 193) 151 38.8 100.6 147 200
ER/PR+HER2− (n= 66) 140.7 36.7 96.5 130.4 200
ER/PR+HER2+ (n= 48) 140.5 34.4 97.5 130.4 200
ER/PR−HER2+ (n= 16) 150.5 39.7 92.5 161.3 –
Association analysis between oncogene expression and pRPA or γ-H2AX
expression in the combined cohort (n= 384) and in breast cancer
subgroups.
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Table 3. Relation between replication stress markers versus oncogene expression and clinicopathological characteristics of the study population.
Univariate (variable: pRPA) Multivariate (variable: pRPA)
Beta 95% CI P value Beta 95% CI P value
Age (continuous) −0.125 −0.684 to [−0.073] 0.015 −0.058 −0.459 to 0.106 0.219
Tumor subgroups 2.44 × 10−7 6.97 × 10−22
ER/PR+HER2− Ref. Ref.
ER/PR+HER2+ 0.037 −7.293 to 14.989 0.497 0.019 −8.136 to 12.126 0.699
ER/PR−HER2− 0.105 0.755–36.488 0.041 0.077 −2.761 to 29.806 0.103
TNBC 0.304 19.817–41.120 3.64 × 10−8 0.198 8.872 to 30.720 4.14 × 10−4
Tumor stage 0.311
I Ref.
II 0.042 −5.638 to 13.349 0.425
III −0.059 −29.687 to 8.204 0.266
Tumor grade 0.006
I Ref. Ref.
II 0.001 −12.632 to 12.902 0.983 −0.019 −12.979 to 9.440 0.756
III 0.165 2.439–27.318 0.019 −0.083 −19.799 to 4.908 0.237
CDC25A −0.055 −0.273 to 0.080 0.284
Cyclin E subgroups 2.66 × 10−8
N−/C− Ref. Ref.
N+/C− 0.155 4.729–29.564 0.007 −0.031 −15.607 to 8.765 0.581
C+ 0.345 20.763–40.844 3.87 × 10−9 0.152 3.876 to 23.371 0.006
c-MYC 0.248 0.167–0.386 1.00 × 10−6 0.154 0.059 to 0.284 0.003
γ-H2AX 0.409 0.421–0.667 1.03 × 10−16 0.373 0.371–0.621 5.57 × 10−14
Univariate (variable: γ-H2AX) Multivariate (variable: γ-H2AX)
Age (continuous) 8.56 × 10−4 −0.229 to 0.233 0.987
Tumor subgroups 0.025 1.11*10−21
ER/PR+HER2− Ref. Ref.
ER/PR+HER2+ 0.024 −6.731 to 10.561 0.663 0.017 −6.299 to 8.930 0.734
ER/PR−HER2− 0.065 −5.284 to 22.448 0.224 −0.008 −13.327 to 11.262 0.869
TNBC 0.163 4.014–20.547 0.004 −0.014 −8.688 to 6.639 0.793
Tumor stage 0.241
I Ref.
II 0.085 −1.265 to 12.995 0.107
III 0.043 −8.351 to 20.105 0.417
Tumor grade 0.058
I Ref.
II 0.007 −9.175 to 10.132 0.922
III 0.127 −0.799 to 18.013 0.073
CDC25A 0.019 −0.108 to 0.158 0.711
Cyclin E subgroups 1.02 × 10−12
N−/C− Ref. Ref.
N+/C− 0.407 24.693–42.859 1.60 × 10−12 0.355 20.800–38.243 1.01*10−10
C+ 0.324 14.414–29.103 1.23 × 10−8 0.201 6.250–20.784 2.92*10−4
c-MYC 0.026 −0.063 to 0.107 0.612
pRPA 0.409 0.238–0.377 1.03 × 10−16 0.368 0.205–0.348 2.17*10−13
(a) Univariate linear regression analyses were performed to analyze the relation between expression of the replication stress markers pRPA or γ-H2AX vs.
clinicopathological characteristics and tumor expression of Cyclin E, c-Myc, or Cdc25A (n= 379). Comparisons with a P value < 0.05 in univariate linear
regression analyses were selected for multivariate linear regression analyses.
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Table 4. Associations between tumor expression and survival.
Univariate (OS) Multivariate (OS)
Beta 95% CI P-value Beta 95% CI P-value
Cyclin E
N−/C− Ref. Ref.
N+/C− 0.633 1.046–3.391 0.035 0.267 0.677–2.519 0.425
C+ 0.219 0.730–2.123 0.422 0.046 0.571–1.921 0.881
Cdc25A
Low Ref. Ref.
High 0.203 0.790–1.898 0.364 0.106 0.692–1.785 0.662
c-Myc
Low Ref. Ref.
High 0.535 1.076–2.712 0.023 0.098 0.632–1.926 0.73
pRPA
Low Ref. Ref.
High 0.131 0.735–1.770 0.558 0.255 0.799–2.085 0.297
γ-H2AX
Low Ref. Ref.
High 0.333 0.890–2.186 0.146 0.284 0.826–2.137 0.241
Univariate (DFS) Multivariate (DFS)
Cyclin E
N−/C− Ref. Ref.
N+/C− 0.565 0.980–3.162 0.058 0.191 0.626–2.340 0.57
C+ 0.127 0.667–1.933 0.64 −0.043 0.525–1.749 0.889
Cdc25A
Low Ref. Ref.
High 0.102 0.715–1.716 0.647 −0.024 0.609–1.563 0.92
c-Myc
Low Ref. Ref.
High 0.555 1.097–2.765 0.019 0.162 0.676–2.043 0.566
pRPA
Low Ref. Ref.
High 0.108 0.719–1.726 0.629 0.09 0.682–1.755 0.708
γ-H2AX
Low Ref. Ref.
High 0.252 0.827–2.001 0.263 0.119 0.707–1.797 0.616
Univariate (RFS) Multivariate (RFS)
Cyclin E
N−/C− Ref. Ref.
N+/C− 0.162 0.621–2.227 0.619 0.083 0.544–2.173 0.813
C+ 0.124 0.673–1.902 0.641 −0.094 0.508–1.630 0.752
Cdc25A
Low Ref. Ref.
High −0.217 0.509–1.274 0.355 −0.212 0.500–1.309 0.388
c-Myc
Low Ref. Ref.
High 0.419 0.955–2.419 0.077 −0.085 0.522–1.616 0.768
pRPA
Low Ref. Ref.
High 0.127 0.723–1.780 0.582 −0.081 0.568–1.497 0.743
γ-H2AX
Low Ref. Ref.
High 0.05 0.671–1.649 0.826 0.04 0.648–1.670 0.870
Univariate Cox regression analyses were performed to analyze the relation between tumor expression of Cyclin E, c-Myc, Cdc25A, pRPA, or γ-H2AX on overall
survival (OS), disease-free survival (DFS) and recurrence-free survival (RFS) on ER/PR+HER2− (n= 159), ER/PR+HER2+ (n= 90), ER/PR−HER2+ (n= 26) and TNBC
(n= 104) breast cancer patients. For multivariate Cox regression analyses, age, tumor size, tumor grade, lymph node involvement, ER status, HER2 status, and
treatment regimen were used as covariates.
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air-dried and fixed in methanol/acetic acid (3:1) for 10min. Next, DNA
spreads were immersed in 2.5 M HCl for 75min. DNA fibers were blocked
in blocking solution (5% bovine serum albumin in PBS) for 30min and
incubated with primary antibodies for 60min at room temperature. CldU
was detected with rat anti-BrdU (1:1000, Abcam, ab6326), whereas IdU was
detected with mouse anti-BrdU (1:250, BD Biosciences, Clone B44).
Secondary antibodies used for detection were Alexa488-conjugated goat
anti-rat IgG (1:500) and Alexa647-conjugated goat anti-mouse IgG (1:500).
Images were acquired on a Leica DM-6000B (63× immersion objective with
1.30 NA) fluorescence microscope, equipped with Leica Application Suite
software. The lengths of 300 IdU tracts were measured per condition using
ImageJ software.
MTT assays
MDA-MB-231 cell lines harboring doxycycline-inducible Cyclin E1 were left
untreated or treated with doxycycline (1 µg/ml) for 48 h. Subsequently,
cells were re-plated in 96-wells at 1000 cells per well in the continued
presence or absence of doxycycline, and allowed to attach for 24 h. ATR
inhibitor VE-822 (Axon) or Wee1 inhibitor MK1775 (Axon) was added at
indicated concentrations for 4 days. Next, cells were incubated with
methylthiazol tetrazolium (MTT, final concentration 0.5 mg/ml) for 4 h.
After removal of medium, formazan crystals were dissolved in dimethyl
sulfoxide (DMSO). Absorbance was measured at 520 nm, and was
quantified using a Benchmark III spectrophotometer (Bio-Rad). MTT
conversion was plotted relative to the untreated cells. Per experiment,
six replicates per condition were included. IC50 values were calculated
using logistic regression model with the ATT Bioquest IC50 tool, with the
minimum response set to zero. A two-sided Students t test was used to
compare IC50 values.
Breast cancer tissue
Immunohistochemical analysis was performed on tissue specimens taken
prior to treatment of 558 patients with breast cancer who underwent
surgery at the University Medical Center Groningen (UMCG). Tissue
collection and storage of clinicopathological and follow up data was only
performed upon patients’ approval via informed consent. Clinical data was
collected in the UMCG and stored digitally in a central database, which is
solely accessible by two dedicated data managers. Statistical analysis was
performed with an anonymized dataset extracted from the central
database. Protection of patient identity was thereby warranted and
according to Dutch law no further Institutional Review Board approval was
necessary. A first cohort (cohort A) consisted of 450 consecutive patients,
of whom tumor specimens were collected between 1996 and 2005,
considering the availability of sufficient paraffin-embedded tissue. A
second cohort (cohort B) consisted of 108 consecutive patients with TNBC,
of whom tumor specimens were collected from 2005 to 2010.
Clinicopathological data gathered in this study was anonymized, and
used in accordance with the Declaration of Helsinki, and in line with the
regulations posed by the Institutional Review Board (IRB) of the UMCG.
Tumor specimens were processed to generate nine tissue microarrays
(TMAs). The first seven TMAs contained samples from cohort A, as
described previously58,59. The final two TMAs contained TNBC cases from
cohort B. For each tumor, three different cores were included in TMAs in a
random fashion.
Immunohistochemistry
TMA slices were deparaffinized using xylene. Slides were incubated for
30min in 0.3% hydrogen peroxidase (H2O2) to suppress endogenous
peroxidase activity. Immunohistochemistry was performed with primary
antibodies against Cdc25A (1:400; rabbit, #sc-97, clone 144; Santa Cruz
Biotechnology, CA, USA), Cyclin E (1:1000; rabbit, #sc-198, clone C19; Santa
Cruz Biotechnology, CA, USA), c-Myc (RTU; rabbit, #790–4628, clone Y69;
Roche, Basel, Switzerland), phospho-RPA32 (Ser33) (1:6400; rabbit, #A300-
246A, clone S33; Bethyl, TX, USA), γ-H2AX (1:300; mouse, #05–636, clone
JBW301; Millipore, Amsterdam, The Netherlands), the AR (RTU; rabbit,
#760–4605, clone SP107; Roche, Basel, Switzerland), 53BP1 (1:300; rabbit,
#IHC-00001; Bethyl, TX, USA) and FANCD2 (1:400; rabbit, #IHC-00624;
Bethyl, TX, USA). Staining was detected by the application of 3,3-
diaminobenzidine (DAB), and hematoxylin as a counterstaining. For c-
Myc and pRPA, the complete staining procedure was performed on an
autostainer (BenchMark Ultra IHC/ISH, Roche, Basel, Switzerland). Addi-
tional information about antibodies and staining protocols is provided in
Supplemental Table 4.
Scoring was performed semi-quantitatively by two independent
researchers, without knowledge of clinical data, and was supervised by a
breast cancer pathologist. Stainings were categorized according to
percentages of cells that showed staining and on intensity of staining.
Staining intensity was scored in three categories: 0 (negative), 1 (medium),
and 2 (high). In order to calculate the score for each core, the percentage
of cells in each group was multiplied by their intensity score, resulting in a
range from 0 to 200 points. Next, the scores from each case and staining
were averaged and considered for analysis.
For Cdc25A, only nuclear staining was considered, in line with a previous
study60. For Cyclin E, nuclear and cytoplasmic staining were scored
individually28. In addition, nuclear c-Myc, pRPA, γ-H2AX, 53BP1, and
FANCD2 stainings were evaluated. A concordance of more than 90% was
found between observers. Discordant scores were reviewed and adjusted
to consensus. The status of ER, PR, HER2, and AR was determined
according to the guidelines of the American Society of Clinical Oncology/
College of American Pathologists by counting at least 100 cells.
Immunohistochemical stainings were considered evaluable when a
tumor core contained at least 10% tumor cells. In addition, tumor stainings
were included for analysis when at least 2 out of 3 cores were evaluable.
Core loss over 558 cases was on average 15.1% (Cdc25A, n= 106 [18.9%];
nuclear Cyclin E, n= 74 [13.2%]; cytoplasmic Cyclin E, n= 82 [14.6%]; c-
Myc, n= 68 [12.1%]; pRPA, n= 77 [13.8%]; and γ-H2AX, n= 99 [17.7%]). For
384 out of 558 cases, all five stainings (pRPA, γ-H2AX, Cyclin E, c-Myc and
Cdc25A) were evaluable. Of 384 cases with complete evaluable
immunohistochemical stainings, 379 had complete clinicopathological
data available, and were included for statistical analysis.
Evaluation of mRNA expression of CCNE1, MYC and CDC25A
Publicly available mRNA profiles of 7270 primary breast tumors were
collected from GEO platforms GPL96 (generated with Affymetrix HG-U133A)
and GPL570 (generated with Affymetrix HG-U133 Plus 2.0) as previously
described33. Expression profiles were batch corrected using COMBAT61.
CCNE1 expression values were calculated using probe 213523_at. CDC25A
expression values were calculated using probe 204695_at. MYC expression
values were calculated using probe 202431_s_at.
Statistical analyses
Analyses were performed on the total study population as well as on four
patient subgroups based on hormone receptor status and HER2
expression. Differences regarding clinicopathological features, treatment,
and immunohistochemical expression levels between the four groups
were analyzed using Pearson chi-square tests in case of categorical
variables, while Kruskal–Wallis tests and Mann–Whitney U tests were used
in case of continuous variables.
Univariate linear regression analyses were performed to study the
relation between expression of replication stress markers versus clinico-
pathological characteristics and tumor expression of Cyclin E, c-Myc, or
Cdc25A. Comparisons that reached P < 0.05 in univariate linear regression
analyses were selected for multivariate linear regression analyses. All
statistical analyses in this study were performed using SPSS Statistics
23.0 (IBM).
Associations between mRNA expression levels and survival in breast
cancer subgroups were determined using multivariate Cox regression
analyses with age, tumor size, tumor grade, lymph node involvement, ER
status, HER2 status, and treatment regimen as co-variates. DFS was
calculated as the interval between date of diagnosis to date of diagnosis of
distant metastasis. RFS was based on the interval between date of
diagnosis of disease to date of diagnosis of DM or date of overall death. OS
was calculated as the interval between date of diagnosis to date of death
by any cause. Survival probabilities for different breast cancer subgroups
were calculated using Kaplan–Meier curves.
Reporting summary
Further information on experimental design is available in the Nature
Research Reporting Summary linked to this paper.
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